Composition for improving perimenopausal symptoms

Abstract

The invention belongs to the technical field of medical supplies, and particularly relates to a composition for improving perimenopausal symptoms. The feed consists of the following components in parts by weight: 400-700 parts of protein substances, 30-50 parts of fat substances, 120-170 parts of carbohydrate substances, 40-90 parts of dietary fiber substances, 30-80 parts of medicinal and edible substances, 2-6 parts of compound trace minerals, 50-95 parts of compound macro minerals, 3-5 parts of compound vitamins and 5-10 parts of blueberry powder. Wherein the protein substance is composed of whey protein, soybean protein and collagen peptide in a mass ratio of (7-12): (6.1-8.5): 1. According to the composition disclosed by the invention, the perimenopausal symptoms such as hectic fever, insomnia, osteoporosis, decrease of estrogen level, uterine atrophy and the like can be remarkably improved by accurately controlling the proportion of soybean protein and collagen peptide in protein.

Description

Technical Field

[0001] The invention belongs to the technical field of medical supplies, and in particular relates to a composition for improving perimenopausal symptoms. Background Art

[0002] Perimenopause refers to the period before and after menopause, including the menopausal transition period and the period after menopause. The average age of Chinese women entering perimenopause is 46 years old, and the average age of menopause is 48-52 years old. About 90% of women go through menopause between the ages of 45 and 55. It is estimated that by 2030, the number of women over 50 will increase to more than 280 million. The essence of menopause is ovarian failure. The decline in estrogen fluctuations and lack of estrogen lead to menopausal symptoms in women, such as menstrual disorders, hot flashes, sweating, sleep disorders, mood changes, and muscle and joint pain throughout the body. In addition, long-term lack of estrogen can increase the risk of metabolic diseases, including calcium metabolism and abnormal sugar and lipid metabolism, such as osteoporosis and cardiovascular and cerebrovascular diseases. About 80% of women have experienced at least one menopausal symptom. The physiological and pathological changes that occur during this stage may have a negative impact on the quality of life of middle-aged women. If not taken seriously, it may lead to serious physical and mental diseases that continue into old age.

[0003] As women's ovarian function gradually declines and estrogen levels drop, the metabolism of various nutrients also changes accordingly, leading to a significant increase in the incidence of various metabolic diseases. Due to the loss of the protective effect of estrogen, women after menopause are more prone to obesity / overweight, metabolic syndrome, insulin resistance, glucose and lipid metabolism disorders, and loss of bone mass and lean body tissue. These special pathophysiological characteristics determine that continuous and reasonable nutritional management with metabolic improvement significance will inevitably play a basic health-promoting role in this special physiological stage of women. Therefore, it is crucial to carry out nutritional health management for perimenopausal women, and to identify and actively intervene in perimenopausal problems early.

[0004] Research reports: The principles of nutritional treatment for perimenopausal women are: Under the premise of ensuring and satisfying the necessary energy for activities, control the total calorie intake, appropriately limit the intake of animal foods, reduce the content of saturated fatty acids and cholesterol in food, ensure sufficient vitamins and minerals, consume more fresh vegetables, and control the amount of salt and cooking oil (Chinese Medical Association Clinical Nutrition Training Program Office, Nutritional Treatment of Perimenopausal Syndrome [J]). However, it takes more time and energy to study and prepare a diet independently under professional advice, while purchasing corresponding nutritional supplements is relatively convenient and time-saving. However, there is currently no nutritional supplement that can be made into daily consumption by combining the ingredients such as protein, carbohydrates, fat, vitamins, etc. that need to be consumed in the diet to improve perimenopausal symptoms for perimenopausal women. Summary of the invention

[0005] In view of the deficiencies and actual needs in the prior art, the present invention proposes a complete nutritional composition specially designed for perimenopausal women. The composition is intended to relieve anxiety and hot flashes in perimenopausal women and improve their sleep conditions.

[0006] To achieve the above objectives, the present invention provides a composition for improving perimenopausal symptoms, which is composed of the following ingredients: 400-700 parts of protein, 30-50 parts of fat, 120-170 parts of carbohydrate, 40-90 parts of dietary fiber, 30-80 parts of food and medicine, 2-6 parts of complex trace minerals, 50-95 parts of complex macro minerals, 3-5 parts of complex vitamins, 5-10 parts of blueberry powder; The protein substance is composed of whey protein, soy protein and collagen peptide in a mass ratio of 7-12:6.1-8.5:1; The carbohydrate substance is composed of maltodextrin and solid corn syrup; The medicine-food homologous substance is composed of wolfberry powder, lily powder, lotus seed powder, longan powder, red date powder and sour jujube kernel powder; The fatty substance is composed of vegetable oil microcapsule powder and fish oil; The vegetable oil microcapsule powder is prepared by mixing medium-chain triglycerides, soybean oil and low-erucic acid rapeseed oil with an edible carrier; The dietary fiber substance is composed of resistant dextrin and oligofructose; The composite trace minerals are prepared by mixing copper sulfate, ferric pyrophosphate, manganese sulfate, sodium selenite, potassium iodide and zinc citrate; The composite macro mineral is prepared by mixing calcium carbonate, magnesium carbonate, potassium citrate and potassium dihydrogen phosphate; The complex vitamin is prepared by mixing vitamin A, vitamin D, vitamin E, vitamin B1, vitamin B2, pantothenic acid, vitamin B6, vitamin B12, vitamin C, biotin, folic acid and niacin.

[0007] Furthermore, it consists of the following ingredients: 400-500 parts of protein, 30-40 parts of fat, 120-130 parts of carbohydrate, 60-70 parts of dietary fiber, 50-60 parts of food and medicine, 3-3.5 parts of complex trace minerals, 70-75 parts of complex macro minerals, 3-4 parts of complex vitamins, 8-8.5 parts of blueberry powder; Furthermore, it consists of the following ingredients: 488 parts of protein substances, 36 parts of fat substances, 121 parts of carbohydrate substances, 62 parts of dietary fiber substances, 58 parts of medicinal and edible substances, 3.1 parts of complex trace minerals, 72 parts of complex macro minerals, 3.5 parts of complex vitamins, and 8.1 parts of blueberry powder.

[0008] Furthermore, the protein substance is composed of whey protein, soy protein and collagen peptide in a mass ratio of 12:8.5:1; Or: whey protein, soy protein and collagen peptide in a mass ratio of 7:6.1:1; Furthermore, the mass ratio of resistant dextrin to oligofructose in the dietary fiber substance is 1-2:1.

[0009] Furthermore, the mass ratio of copper sulfate, ferric pyrophosphate, manganese sulfate, sodium selenite, potassium iodide and zinc citrate in the composite trace minerals is 7-8:15-16:45-46:5-6:9-10:10; The mass ratio of calcium carbonate, magnesium carbonate, potassium citrate and potassium dihydrogen phosphate in the composite macro-mineral is 1-2:0.5-1:1-2:1.

[0010] Furthermore, the mass ratio of medium-chain triglycerides, soybean oil, low-erucic acid rapeseed oil and fish oil in the fat substance is 5-6:7-8:2-3:1; and the edible carrier is maltooligosaccharide.

[0011] Furthermore, the mass ratio of vitamin A, vitamin D, vitamin E, vitamin B1, vitamin B2, pantothenic acid, vitamin B6, vitamin B12, vitamin C, biotin, folic acid and niacin in the vitamin complex is 0.5~0.6:0.008~0.009:18~19:1~2:1~2:4~5:3~4:0.003~0.005:72~73:0.02~0.04:0.2~0.3:10.

[0012] Furthermore, the mass ratio of wolfberry powder, lily powder, lotus seed powder, longan powder, red date powder and wild jujube seed powder in the medicine-food substance is 6-7:8-9:8-9:7-8:12-13:10; The mass ratio of maltodextrin to solid corn syrup in the carbohydrate material is 2-3:1.

[0013] The present invention also provides a use of the aforementioned composition in preparing food or medicine for improving perimenopausal symptoms, wherein the perimenopausal symptoms include hot flashes, insomnia, osteoporosis, decreased estrogen levels, and uterine atrophy.

[0014] The "red dates" described in the present invention are a type of jujube in the catalogue of medicinal and edible homology, and are red or dark red in appearance.

[0015] Beneficial effects of the present invention: The composition of the present invention selects a variety of high-quality proteins, among which soy protein is rich in soy isoflavones, which can relieve symptoms such as hot flashes and night sweats, improve ovarian function, prevent osteoporosis, and support cardiovascular health; whey protein is rich in a variety of essential amino acids and bioactive substances, provides high-quality protein, improves immunity, and helps promote calcium absorption, thereby increasing bone density; collagen peptides are specially added, which are easy to digest and absorb, and can also promote collagen synthesis in the body, relieve skin aging and bone and joint problems; soluble dietary fiber improves the intestinal flora environment and effectively controls blood sugar and body weight levels; omega-3 fatty acids in fish oil, It helps relieve hot flashes and mood swings, and reduces the risk of cardiovascular disease; multiple vitamins and minerals, vitamin D and calcium help maintain bone density and prevent osteoporosis; vitamin A, vitamin E, selenium and zinc have antioxidant effects, support immune function, and protect cardiovascular health; blueberry powder has antioxidant and anti-inflammatory effects; wolfberry powder is a substance of medicinal and edible origin, nourishes the liver and kidneys, improves the eyesight, and can relieve perimenopausal symptoms such as dizziness and tinnitus; lily powder, lotus seed powder, and jujube seed powder nourish the heart and calm the mind, and help relieve symptoms such as sleep disorders, palpitations and fatigue; longan powder and red date powder replenish the middle and replenish qi, and can improve forgetfulness and insomnia symptoms. These effective ingredients are combined in a specific ratio, especially soy protein and collagen peptides in protein. When the protein content is certain, by precisely controlling the ratio of the two, it can significantly improve perimenopausal symptoms such as hot flashes, insomnia, osteoporosis, decreased estrogen levels, and uterine atrophy. Animal experiments have shown that the effects of the various components in the composition of the present invention are affected by the proteins, soy protein and collagen peptides. When the protein in the composition consists of whey protein, soy protein and collagen peptides, and the mass ratio of the three proteins is controlled at 7-12:6.1-8.5:1, the various effective components work synergistically and are effective in improving perimenopausal symptoms. In particular, when the mass ratio of whey protein, soy protein and collagen peptides is 12:8.5:1, the improvement effect on various symptoms during perimenopause is particularly prominent, and the composition has practical value for promotion and application.

[0016] Obviously, according to the above contents of the present invention, in accordance with common technical knowledge and customary means in the art, without departing from the above basic technical ideas of the present invention, other various forms of modification, replacement or change may be made.

[0017] The above contents of the present invention are further described in detail below through specific implementation methods in the form of embodiments. However, this should not be understood as the scope of the above subject matter of the present invention being limited to the following examples. All technologies realized based on the above contents of the present invention belong to the scope of the present invention. BRIEF DESCRIPTION OF THE DRAWINGS

[0018] Figure 1 A graph of rat tail skin temperature; Figure 2 Diagram of rat uterine index; Figure 3 Figure 1 shows the results of the rat E2 assay; Figure 4 Figure of the FSH and LH test results of rats; Figure 5 Figure 1 shows the results of femoral bone density testing in rats; Figure 6 Plot of sleep latency and sleep duration in mice. DETAILED DESCRIPTION

[0019] The raw materials and equipment in the specific embodiment of the present invention can be obtained by commercial purchase, wherein low-erucic acid rapeseed oil is rapeseed oil with an erucic acid content not exceeding 3% of the fatty acid composition; oligofructose is an oligosaccharide formed by combining sucrose and 1 to 3 fructose groups with the fructose group in sucrose through a β-(2→1)-glycosidic bond; and oligomaltose is an oligosaccharide composed of more than 3 and less than 10 glucose groups connected by an α-1,4 glycosidic bond.

[0020] Example 1 Preparation of the nutritional composition of the present invention Formula: 488 parts of protein, 36 parts of fat, 121 parts of carbohydrate, 62 parts of dietary fiber, 58 parts of medicinal and edible substances, 3.1 parts of complex trace minerals, 72 parts of complex macro minerals, 3.5 parts of complex vitamins, 8.1 parts of blueberry powder; Among them, the protein substance is composed of whey protein, soy protein and collagen peptide in a mass ratio of 12:8.5:1, that is, 272.37 parts of whey protein, 192.93 parts of soy protein and 22.70 parts of collagen peptide; The fat substance is composed of vegetable oil microcapsule powder and fish oil; the vegetable oil microcapsule powder is made by mixing medium-chain triglycerides, soybean oil and low-erucic acid rapeseed oil with an edible carrier maltooligosaccharide; the mass ratio of medium-chain triglycerides, soybean oil, low-erucic acid rapeseed oil and fish oil in the fat substance is 5.2:7.1:2.5:1, that is, 9.8 parts of medium-chain triglycerides, 13.4 parts of soybean oil, 4.8 parts of low-erucic acid rapeseed oil, 1.9 parts of fish oil, and the rest is maltooligosaccharide.

[0021] The carbohydrate substance is composed of maltodextrin and solid corn syrup in a mass ratio of 2.8:1, that is, 89.2 parts of maltodextrin and 31.8 parts of solid corn syrup; The dietary fiber substance is composed of resistant dextrin and oligofructose in a mass ratio of 1.64:1, that is, 38.5 parts of resistant dextrin and 23.5 parts of oligofructose; The medicine-food homologous substance is composed of wolfberry powder, lily powder, lotus seed powder, longan powder, red date powder, and wild jujube seed powder in a mass ratio of 6.2:8.1:8.6:7.4:12.1:10, that is, 6.86 parts of wolfberry powder, 8.97 parts of lily powder, 9.52 parts of lotus seed powder, 8.19 parts of longan powder, 13.39 parts of red date powder, and 11.07 parts of wild jujube seed powder; The composite trace minerals are composed of copper sulfate, ferric pyrophosphate, manganese sulfate, sodium selenite, potassium iodide, and zinc citrate in a mass ratio of 7.38:15.93:45.24:5.07:9.10:10, namely 0.2467 parts of copper sulfate, 0.5326 parts of ferric pyrophosphate, 1.5126 parts of manganese sulfate, 0.1695 parts of sodium selenite, 0.3043 parts of potassium iodide, and 0.3343 parts of zinc citrate; The complex macro-minerals are composed of calcium carbonate, magnesium carbonate, potassium citrate, and potassium dihydrogen phosphate in a mass ratio of 1.85:0.53:1.58:1, i.e. 26.85 parts of calcium carbonate, 7.69 parts of magnesium carbonate, 22.94 parts of potassium citrate, and 14.52 parts of potassium dihydrogen phosphate; The multivitamin is composed of vitamin A, vitamin D, vitamin E, vitamin B1, vitamin B2, pantothenic acid, vitamin B6, vitamin B12, vitamin C, biotin, folic acid and niacin in a mass ratio of 0.55:0.009:18.21:1.35:1.26:4.62:3.5:0.004:72.16:0.03:0.28:10, namely 0.0172 parts of vitamin A, 0.0003 parts of vitamin D, 0.5692 parts of vitamin E, 0.042 parts of vitamin B1, 0.0394 parts of vitamin B2, 0.1444 parts of pantothenic acid, 0.1094 parts of vitamin B6, 0.0001 parts of vitamin B12, 2.2555 parts of vitamin C, 0.0009 parts of biotin, 0.0088 parts of folic acid and 0.3126 parts of niacin.

[0022] Preparation method: weigh the raw materials according to the ratio, and add fish oil, complex vitamins, complex trace minerals, wolfberry powder, lily powder, blueberry powder, red date powder, lotus seed powder, longan powder, jujube kernel powder, maltodextrin, complex macro minerals, solid corn syrup, vegetable oil microcapsule powder, resistant dextrin, oligofructose, and collagen peptide in turn, and mix for 30 minutes; then add whey protein and soy protein, mix for 60 minutes to obtain the finished product.

[0023] Example 2 Preparation of the nutritional composition of the present invention This embodiment is basically the same as Embodiment 1, except that the protein substance is composed of whey protein, soy protein and collagen peptide in a mass ratio of 7:6.1:1, i.e., 242.27 parts of whey protein, 211.12 parts of soy protein and 34.61 parts of collagen peptide, and the rest is the same as Embodiment 1.

[0024] Comparative Example 3 Preparation of the nutritional composition of the present invention This embodiment is basically the same as Embodiment 1, except that the protein substance is composed of whey protein, soy protein and collagen peptide in a mass ratio of 4.5:2.7:1, i.e., 267.80 parts of whey protein, 160.68 parts of soy protein and 59.51 parts of collagen peptide, and the rest is the same as Embodiment 1.

[0025] Comparative Example 4 Preparation of the nutritional composition of the present invention This embodiment is basically the same as the embodiment 1, except that the protein material is 488 portions of whey protein, and the rest is the same as the embodiment 1.

[0026] The beneficial effects of the present invention are further illustrated by experimental examples below: Test Example 1 Study on the effect of the nutritional composition of the present invention on improving perimenopausal symptoms 1. Experimental methods 60 SPF-grade 2-month-old female SD rats were purchased, with a mass of 180-220 g at the time of purchase; SPF-grade 1-month-old female ICR mice were purchased with a mass of 19-23 g at the time of purchase. The animals were raised in a clean environment with constant temperature and humidity (temperature 22-25°C, humidity 65%-70%), and maintained with 12 hours of light and 12 hours of darkness day and night alternation, and raised in a well-ventilated environment, with free food and water.

[0027] After one week of adaptive feeding, rats and mice were randomly divided into 6 groups (10 in each group), rats: blank control group (sham operation group), model group, Example 1 group, Example 2 group, Comparative Example 3 group, Comparative Example 4 group; mice: blank control group (sham operation group), model group, Example 1 group, Example 2 group, Comparative Example 3 group, Comparative Example 4 group. The model group, Example 1 group, Example 2 group, Comparative Example 3 group and Comparative Example 4 group rats and mice were cut open, bilateral ovaries were removed and sutured to construct perimenopausal model rats and mice. The blank control group (sham operation group) rats and mice were cut open and part of the fat tissue around the ovaries was removed and sutured. Antibiotics were injected for three consecutive days after surgery to prevent infection.

[0028] Intervention began one week after surgery. Rats and mice in Example 1, Example 2, Comparative Example 3, and Comparative Example 4 groups were gavaged with aqueous solutions (0.2 g / ml) of the nutrient compositions of Example 1, Example 2, Comparative Example 3, and Comparative Example 4, respectively, at a dose of 2 g / kg·BW. Rats and mice in the blank control group and the model group were gavaged with an equal amount of distilled water daily. Rats were gavaged continuously for 12 weeks, and mice were gavaged continuously for 4 weeks.

[0029] The formula of the nutritional composition administered by gavage to each medication group is as follows: Table 1 List of dosing formulas for each group For rats, 24 hours after the last intragastric administration, the body weight was weighed and the skin temperature of the tail was measured. After anesthesia, blood was collected from the abdominal aorta to separate the serum and then stored. The uterus was removed, weighed, recorded, and stored at -80°. After killing, the femur of the right leg of the rat was removed, the muscles and soft tissues attached to the surface were removed, and stored in 4% paraformaldehyde for subsequent experimental detection.

[0030] For mice, 1 hour after the last gavage, each group of mice was intraperitoneally injected with a threshold dose of sodium pentobarbital (40 mg / kg). The disappearance of the righting reflex of the mice was used as the indicator of falling asleep, and the recovery of the righting reflex of the mice was used as the indicator of awakening. The sleep latency and sleep duration of each group of mice were recorded.

[0031] 1.1 Tail temperature Hot flashes are one of the typical symptoms of perimenopausal syndrome in women, accompanied by other symptoms such as chest tightness and irritability, which affect the quality of life. The skin temperature of the rat tail was measured to evaluate the effect of intervention on the improvement of hot flashes in perimenopausal rats.

[0032] The results of rat tail skin temperature are as follows Figure 1 As shown, the tail temperature of the rats in the model group increased significantly, which was higher than that in the control group (P<0.05), and the tail temperatures of the other four groups increased to varying degrees. The tail temperatures of the rats in Example 1 and Example 2 were significantly lower than those in the model group (P<0.05), indicating that Example 1 and Example 2 can effectively inhibit the abnormal increase in body temperature of perimenopausal rats and relieve hot flashes. The tail temperature of the rats in Example 1 was lower than that in Example 2, and the effect was more significant.

[0033] 1.2 Uterine index The rat uterine index (i.e., the ratio of uterine weight to body weight) is an important parameter reflecting the perimenopausal status and estrogen levels. During perimenopause, due to the decline of ovarian function and the decrease in estrogen secretion, the uterus atrophies and the uterine index decreases significantly. The wet weight of the rat uterus is weighed and the ratio to body weight is calculated as the uterine index, which reflects the development of the uterus and evaluates the effect of interventions on the uterine development of perimenopausal model rats.

[0034] The results of rat uterine index are as follows Figure 2 As shown, the uterine index of the model group was significantly lower than that of the control group (P<0.05), and the uterine index of Example 1 and Example 2 groups was significantly higher than that of the model group (P<0.05). Comparative Example 3 and Comparative Example 4 groups could improve the uterine index of perimenopausal model rats to a certain extent, but without significant significance. The intervention substance of Example 1 group can effectively promote the normal development of the uterus and relieve perimenopausal symptoms, and the effect is better than that of Example 2 group.

[0035] 1.3 Estradiol (E2) Estradiol (E2) is an important female hormone, belonging to the steroid hormone, secreted by the follicular cells of the ovaries, and is the most biologically active type of estrogen. Estradiol plays a vital role in menstrual regulation, reproductive health, bone metabolism, and cardiovascular protection. After entering the perimenopausal period, ovarian function is gradually lost, and E2 levels drop sharply, leading to a series of perimenopausal symptoms, including hot flashes, night sweats, osteoporosis, and increased risk of cardiovascular disease. The ELISA kit was used to detect the E2 level in the serum of each group of rats to evaluate the effect of the intervention on E2 in the perimenopausal model rats.

[0036] The results of rat E2 test are as follows Figure 3 As shown, the E2 level in the model group was significantly lower than that in the control group (P<0.05), the level in the Example 1 group was close to that in the control group and significantly higher than that in the model group (P<0.05), and the E2 level in the Example 2 group was also significantly higher than that in the model group (P<0.05), but lower than that in the Example 1 group. This indicates that the intervention in the Example 1 group has the best effect in improving the E2 level of rats and improving the decline in estrogen levels during perimenopause, followed by the Example 2 group. The comparison groups 3 and 4 had no significant effect in improving the decline in estrogen levels during perimenopause.

[0037] 1.4 Serum follicle-stimulating hormone (FSH) and luteinizing hormone (LH) The levels of rat serum follicle-stimulating hormone (FSH) and luteinizing hormone (LH) are important physiological indicators for evaluating the perimenopausal state. Perimenopausal syndrome can lead to abnormal increases in FSH and LH, disrupt hormone balance, and aggravate perimenopausal syndrome and affect health. Using ELISA kits to detect rat serum FSH and LH can indirectly reflect their estrogen secretion and perimenopausal state.

[0038] The results of FSH and LH test in rats are as follows Figure 4 As shown, the FSH and LH in the model group were significantly higher than those in the control group (P<0.05), the FSH and LH in the Example 1 group were significantly lower than those in the model group (P<0.05), and the FSH in the Example 2 group was significantly different from that in the model group, but slightly higher than that in the Example 1 group. This shows that the Example 1 group has the best effect in inhibiting the abnormal increase of FSH and LH in perimenopausal rats and maintaining hormone balance, followed by the Example 2 group. The comparison groups 3 and 4 had no obvious effect in maintaining the estrogen hormone balance in perimenopausal rats.

[0039] 1.5 Femoral bone density Perimenopausal osteoporosis is a common disease caused by an imbalance in bone metabolism due to a decrease in estrogen levels, which is mainly manifested by decreased bone density and destruction of bone structure, thereby increasing the risk of fractures. Dual-energy X-ray absorptiometry was used to measure the midpoint and distal bone density of rat femurs to evaluate the effects of various interventions on bone density in perimenopausal rats.

[0040] The results of rat femoral bone density test were as follows Figure 5 As shown, the femoral density of the model group was significantly lower than that of the control group (P<0.05), and the femoral distal end and midpoint bone density of the Example 1 group were significantly higher than those of the model group (P<0.05), and higher than those of the Example 2 group, the Comparative Example 3 group and the Comparative Example 4 group. The femoral distal end bone density of the Example 2 group was significantly different from that of the model group (P<0.05). This shows that Example 1 has the best effect in improving the bone density of perimenopausal rats and preventing osteoporosis, followed by the Example 2 group. Comparative Example 3 and 4 groups have no obvious effect in improving perimenopausal bone density.

[0041] 1.6 Mouse sleep experiment Insomnia is one of the important symptoms of perimenopausal syndrome. Patients experience difficulty falling asleep, waking up easily at night, and having many dreams, which seriously affect their quality of life. After intervention, a pentobarbital sodium sleep time extension experiment was conducted on mice to evaluate the effects of each group of interventions on the sleep of perimenopausal model mice.

[0042] Sleep latency and sleep duration in mice Figure 6 As shown, compared with the control group, the model group had a significantly prolonged sleep latency (P<0.05) and a significantly shortened sleep time (P<0.05). Both Example 1 and Example 2 groups were able to shorten the sleep latency and prolong the sleep time, and the difference compared with the model group was significant (P<0.05). The sleep latency of Example 1 group was shorter and the sleep time was longer than that of Example 2 group, and the effect was more significant. Comparative Examples 3 and 4 groups had no significant effect on improving perimenopausal sleep.

[0043] The above results show that the intervention substances in Example 1 and Example 2 can promote uterine development in perimenopausal model rats, improve estrogen secretion, maintain hormone balance, relieve perimenopausal hot flashes and enhance bone density. It also has the effect of improving insomnia in perimenopausal mice, shortening sleep latency and prolonging sleep time. It can be seen that both Example 1 and Example 2 have the effect of relieving and treating perimenopausal syndrome, and the intervention effect of Example 1 is better.

[0044] The main difference between the compositions of Examples 1-2 and Comparative Example 4 used in the animal experiment is the presence or absence of soy protein and collagen peptide in the protein, indicating that the soy protein and collagen peptide in the composition have an important influence on the intervention effect; the main difference between the compositions of Examples 1-2 and Comparative Example 3 is that the ratio of soy protein and collagen peptide in the protein is different. The soy protein in the composition of Comparative Example 3 is 160.68 parts, which is significantly lower than the soy protein of 192.93-211.12 parts in the compositions of Examples 1-2, and the collagen peptide is 59.51 parts, which is significantly higher than the compositions of Examples 1-2. The compositions of Examples 1 and 2 contain 22.70 to 34.61 parts of collagen peptides, indicating that the addition of soy protein and collagen peptides while controlling the ratio of the two proteins is required to improve perimenopausal symptoms; the main difference between the composition of Example 1 and the composition of Example 2 is that the proportion of whey protein in the protein is different. The composition of Example 2 contains 242.27 parts of whey protein, which is significantly lower than the 272.37 parts of whey protein in the composition of Example 1, indicating that controlling the ratio of soy protein and collagen peptides in the protein while controlling the proportion of whey protein can maximize the improvement effect of the symptoms of perimenopausal syndrome.

[0045] In summary, the composition of the present invention is formulated by integrating the nutritional functional characteristics of each component, and on this basis, when the mass ratio of whey protein, soy protein and collagen peptide is controlled at 7-12:6.1-8.5:1, the effective ingredients work synergistically and are effective in improving perimenopausal symptoms, especially when the mass ratio of whey protein, soy protein and collagen peptide is 12:8.5:1, the improvement effect of various symptoms in perimenopause is particularly prominent, and it has practical promotion and application value.

Claims

1. A composition for improving perimenopausal symptoms, characterized in that: It is composed of the following ingredients: 400-700 parts of protein, 30-50 parts of fat, 120-170 parts of carbohydrate, 40-90 parts of dietary fiber, 30-80 parts of food and medicine, 2-6 parts of complex trace minerals, 50-95 parts of complex macro minerals, 3-5 parts of complex vitamins, 5-10 parts of blueberry powder; The protein substance is composed of whey protein, soy protein and collagen peptide in a mass ratio of 7-12:6.1-8.5:1; The carbohydrate substance is composed of maltodextrin and solid corn syrup; The medicine-food homologous substance is composed of wolfberry powder, lily powder, lotus seed powder, longan powder, red date powder and sour jujube kernel powder; The fatty substance is composed of vegetable oil microcapsule powder and fish oil; The vegetable oil microcapsule powder is prepared by mixing medium-chain triglycerides, soybean oil and low-erucic acid rapeseed oil with an edible carrier; The dietary fiber substance is composed of resistant dextrin and oligofructose; The composite trace minerals are prepared by mixing copper sulfate, ferric pyrophosphate, manganese sulfate, sodium selenite, potassium iodide and zinc citrate; The composite macro minerals are prepared by mixing calcium carbonate, magnesium carbonate, potassium citrate and potassium dihydrogen phosphate; The complex vitamin is prepared by mixing vitamin A, vitamin D, vitamin E, vitamin B1, vitamin B2, pantothenic acid, vitamin B6, vitamin B12, vitamin C, biotin, folic acid and niacin.

2. The composition according to claim 1, characterized in that: It is composed of the following ingredients: 400~500 parts of protein, 30~40 parts of fat, 120~130 parts of carbohydrates, 60~70 parts of dietary fiber, 50~60 parts of edible and medicinal substances, 3~3.5 parts of complex trace minerals, 70~75 parts of complex macro minerals, 3~4 parts of complex vitamins, and 8~8.5 parts of blueberry powder.

3. The composition according to claim 2, characterized in that: It is composed of the following ingredients: 488 parts of protein substances, 36 parts of fat substances, 121 parts of carbohydrate substances, 62 parts of dietary fiber substances, 58 parts of medicinal and edible substances, 3.1 parts of complex trace minerals, 72 parts of complex macro minerals, 3.5 parts of complex vitamins, and 8.1 parts of blueberry powder.

4. The composition according to claim 1, characterized in that: The proteinaceous substance is composed of a mass ratio of 12: 8.5:1 composition of whey protein, soy protein and collagen peptides; Or: whey protein, soy protein and collagen peptide in a mass ratio of 7:6.1:

1.

5. The composition according to claim 1, characterized in that: The mass ratio of resistant dextrin to oligofructose in the dietary fiber material is 1-2:

1.

6. The composition according to claim 1, characterized in that: The mass ratio of copper sulfate, ferric pyrophosphate, manganese sulfate, sodium selenite, potassium iodide and zinc citrate in the composite trace minerals is 7-8:15-16:45-46:5-6:9-10:10; The mass ratio of calcium carbonate, magnesium carbonate, potassium citrate and potassium dihydrogen phosphate in the composite macro-mineral is 1-2:0.5-1:1-2:

1.

7. The composition according to claim 1, characterized in that: The mass ratio of medium-chain triglycerides, soybean oil, low-erucic acid rapeseed oil and fish oil in the fat substance is 5-6:7-8:2-3:1; and the edible carrier is maltooligosaccharide.

8. The composition according to claim 1, characterized in that: The mass ratio of vitamin A, vitamin D, vitamin E, vitamin B1, vitamin B2, pantothenic acid, vitamin B6, vitamin B12, vitamin C, biotin, folic acid and nicotinic acid in the complex vitamin is 0.5-0.6: 0.008-0.009: 18-19: 1-2: 1-2: 4-5: 3-4: 0.003-0.005: 72-73: 0.02-0.04: 0.2-0.3:

10.

9. The composition according to claim 1, characterized in that: The mass ratio of wolfberry powder, lily powder, lotus seed powder, longan powder, red date powder and wild jujube seed powder in the medicine and food homologous substances is 6-7:8-9:8-9:7-8:12-13:10; The mass ratio of maltodextrin to solid corn syrup in the carbohydrate material is 2-3:

1.

10. Use of the composition according to any one of claims 1 to 8 in the preparation of food or medicine for improving perimenopausal symptoms, characterized in that: The perimenopausal symptoms include hot flashes, insomnia, osteoporosis, decreased estrogen levels, and uterine atrophy.

Images